Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Lo-Coco

Showing results (151-160 of 204) with videos related to

Pageof 21
Sort By:
Leukemia|December 22, 2018
Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemiaFabio Efficace, Massimo Breccia, Giuseppe Avvisati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2009
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapyDavid Grimwade, Jelena V Jovanovic, Robert K Hills, et al.
Blood|August 30, 2002
Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experienceAlessandro Pulsoni, Livio Pagano, Francesco Lo Coco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2015
A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid LeukemiaDaniela F Angelini, Tiziana Ottone, Gisella Guerrera, et al.
Cancer Research|September 5, 2006
Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemiaGiuseppe Cimino, Francesco Lo-Coco, Susanna Fenu, et al.
Blood|November 4, 2009
Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemiaAshley N Mays, Neil Osheroff, Yuanyuan Xiao, et al.
Genes, Chromosomes & Cancer|June 15, 2010
Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: association of DNA breaks with specific DNA motifs at PML and RARA lociSyed Khizer Hasan, Tiziana Ottone, Richard F Schlenk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2008
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemiaLuca Maurillo, Francesco Buccisano, Maria Ilaria Del Principe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2014
Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomesFabio Efficace, Franco Mandelli, Giuseppe Avvisati, et al.
American Journal of Hematology|November 8, 2014
Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemiaLuca Maurillo, Francesco Buccisano, Alfonso Piciocchi, et al.
Pageof 21

Showing results (151-160 of 204) with videos related to

Sort By:
Pageof 21
Leukemia|December 22, 2018
Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemiaFabio Efficace, Massimo Breccia, Giuseppe Avvisati, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2009
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapyDavid Grimwade, Jelena V Jovanovic, Robert K Hills, et al.
Blood|August 30, 2002
Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experienceAlessandro Pulsoni, Livio Pagano, Francesco Lo Coco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2015
A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid LeukemiaDaniela F Angelini, Tiziana Ottone, Gisella Guerrera, et al.
Cancer Research|September 5, 2006
Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemiaGiuseppe Cimino, Francesco Lo-Coco, Susanna Fenu, et al.
Blood|November 4, 2009
Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemiaAshley N Mays, Neil Osheroff, Yuanyuan Xiao, et al.
Genes, Chromosomes & Cancer|June 15, 2010
Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: association of DNA breaks with specific DNA motifs at PML and RARA lociSyed Khizer Hasan, Tiziana Ottone, Richard F Schlenk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2008
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemiaLuca Maurillo, Francesco Buccisano, Maria Ilaria Del Principe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2014
Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomesFabio Efficace, Franco Mandelli, Giuseppe Avvisati, et al.
American Journal of Hematology|November 8, 2014
Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemiaLuca Maurillo, Francesco Buccisano, Alfonso Piciocchi, et al.
Pageof 21